Triple-negative breast cancer: new perspectives for targeted therapies.

Onco Targets Ther · 2015 · PMC4303459 · PMID 25653541

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Furthermore, in some trials cetuximab showed a positive trend to an OS advantage in this setting, even if those trials enrolled only a small number of patients.

also in 11,005 other papers

showed a trendno p-value reported

In conclusion, adding everolimus to neoadjuvant paclitaxel showed a trend toward an improvement in the 12-week RR, but it did not improve the pCR rate in TNBC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.